Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The delta-subunit of the epithelial sodium channel (ENaC) enhances channel activity and alters proteolytic ENaC activation.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.
Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain.
Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Laquinimod
SIRT1 deacetylates RORγt and enhances Th17 cell generation.
Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.
Receptos, Inc. - Current Report: United States Securities and Exchange Commission Form 8-K
Axonal conduction and injury in multiple sclerosis: the role of sodium channels.
Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: a large international survey.
Genzyme's Lemtrada resubmission accepted for review by FDA
T cells become licensed in the lung to enter the central nervous system.
Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.
Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody.
Risk factors for rare diseases can be risky to define: PML and natalizumab.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Daclizumab (anti-CD25) in multiple sclerosis.

Pages